Hauv cov toj roob hauv pes ntawm kev txhim kho cov kab mob metabolic, GLP-1 receptor agonists tau tsim lawv tus kheej li "tus qauv kub" rau kev poob phaus thiab tswj ntshav qab zib, tab sis qhov ua tau zoo ntawm cov tshuaj ib leeg muaj lub qab nthab. Lub advent ntawmMazdutidesawv cev rau kev hloov kho lub tswv yim ntawm "metabolic reprogramming"- nws yog ob qho tib si agonist ntawm GLP-1 thiab glucagon receptors. Los ntawm tib lub sijhawm ua rau ob txoj hauv kev sib txuas ua ke hauv metabolic, nws tsis tsuas yog txo qis qab los noj mov thiab qeeb plab hnyuv, tab sis kuj tseem ua rau lub zog siv zog hauv daim siab thiab cov ntaub so ntswg adipose, yog li ua tiav qhov hnyav dua thiab txhim kho metabolic.
🧬 Molecular profile ntawm GLP-1/GCGR dual-target chimeric peptide
Tag nrho cov pob txha polypeptide tau sib sau ua ke ua tiav cov amino acid ib ntus los ntawm cov khoom siv -theem, kauj ruam- los ntawm - kauj ruam condensation cov tshuaj tiv thaiv. Ib pawg isobutyric acid amino yog qhia nyob rau ntawm qhov thib ob amino acid qhov chaw, tsim ib qho steric barrier uas cuam tshuam qhov cleavage thiab degradation ntawm N-terminus ntawm peptide saw los ntawm dipeptidyl peptidase 4. Qhov no txhim kho polypeptide's anti-enzymatic stability nyob rau hauv lub cev mocular ntau tshaj ntawm cov kua dej hauv lub cev. gastric acid regulators raug metabolized thiab inactivated nyob rau hauv feeb. Hauv cov tshuaj aqueous, linear polypeptide saw spontaneously tsim cov qauv hauv zos -helical theem nrab raws li hydrophobic amino acid residues. Qhov kev ua kom zoo li niaj zaus no tso cai rau kev nkag mus rau hauv cov khoom sib txuas ntxiv ntawm ob lub G protein -coupled receptors, ua kom muaj kev sib luag agonistic ua haujlwm tawm tsam ob qho tib si GLP-1 thiab glucagon receptors thiab zam kev pheej hmoo ntawm cov ntshav qabzib hloov pauv los ntawm overactivation ntawm ib lub hom phiaj.
Cov dej molecular solubility yog txiav txim los ntawm ob qho tib si polar amino acid residues thiab lub davhlau ya nyob twg hloov pawg.Mazdutidepom zoo solubility nyob rau hauv cov dej ntshiab thiab tau ncaj qha formulated rau hauv nruab nrab buffered saline txhaj. Qhov ntev fatty acid sab chains tsuas yog siv los khi rau plasma albumin kom ntev ib nrab -lub neej thiab tsis ua rau tag nrho cov lipid solubility, yog li tsis cuam tshuam rau kev npaj formulation. Tom qab txhaj tshuaj subcutaneous, cov tshuaj maj mam nqus mus rau hauv cov hlab ntsha ntawm diffusion los ntawm cov ntaub so ntswg subcutaneous. Cov fatty acid chains tsis yog-covalently khi rau circulating albumin, tsim ib tug loj, sustained - tso tawm complex uas bypasses ceev glomerular pom. Peak plasma concentrations tau mus txog 6 mus rau 31 teev tom qab kev tswj hwm, thiab khov kho -lub xeev cov ntshav ntshav siab tau ua tiav nrog plaub lub lis piam ntawm kev noj tshuaj tas mus li. Txoj kev nkhaus maj mam txo qis qhov tshwm sim ntawm qhov tshwm sim tsis zoo xws li plab hnyuv thiab lub plawv dhia hloov pauv.
Cov hmoov lyophilized nthuav tawm cov tshuaj lom neeg ruaj khov zoo nyob rau hauv chav tsev kub, lub teeb - tiv thaiv, thiab kaw qhov chaw cia. Cov peptide bonds nyob rau hauv cov pob txha polypeptide tsis yooj yim hydrolyzed los yog tawg nyob rau hauv ib txwm cia kub thiab av noo. Yooj yim oxidized aromatic amino acid residues xws li tyrosine thiab tryptophan qhia tsis tshua muaj oxidation tus nqi nyob rau hauv cov pa oxygen - ib puag ncig dawb ntawm lub tshuab nqus tsev khov - ziab. Peptide saw breakage thiab sab- chain group modification and degradation tsuas yog tshwm sim nyob rau hauv siab -kub, muaj zog acid, muaj zog alkali, thiab ntev da dej tej yam kev mob. Lub sijhawm ntev- khaws cia tsis tsim cov tshuaj muaj feem cuam tshuam, txo cov pov tseg thiab poob ntawm cov khoom xyaw tshuaj nquag (APIs). Cov tuam txhab lag luam tuaj yeem muab cov khoom lag luam hauv nruab nrab thiab khaws cov APIs no hauv qhov ntau, txo cov nqi kev tswj hwm cov khoom lag luam cuam tshuam nrog kev rov ua dua tshiab. Ib txhij, nws tshem tawm txoj kev pheej hmoo ntawm kev ua xua, khaus khaus hauv zos, thiab lwm yam kev nyab xeeb ntawm cov tshuaj uas tshwm sim los ntawm degradation impurities contaminating injectable formulations, ua tau raws li kev tswj hwm kev ruaj ntseg rau kev txhaj tshuaj APIs.
Qhov sib npaug ntawm qhov sib npaug ntawm ob lub receptors yog kaw ncaj qha los ntawm spatial folding morphology ntawm cov saw peptide. Ob qhov kawg ntawm cov qauv helical sib raug rau thaj tsam kev lees paub ntawm ob lub receptors, thiab kev ua kom muaj zog ntawm ob lub hom phiaj yog qhov sib npaug thaum lub sijhawm hloov pauv molecular. Cov nyhuv hypoglycemic ntawm GLP-1 receptor counteracts lub peev xwm hyperglycemic nyhuv ntawm glucagon receptor, ua tiav cov txiaj ntsig tseem ceeb ntawm kev ruaj khov thiab tswj cov ntshav qab zib thaum poob phaus. Cov txheej txheem purification kom huv si tshem tawm cov txheej txheem zoo sib xws truncated peptide impurities, tiv thaiv impurities los ntawm kev sib tw nyob rau hauv qhov chaw receptor khi thiab ua kom tsis muaj zog. Qhov no tso cai rau Mazdutide los nthuav tawm cov tshuaj ntshiab thiab ruaj khov- cov lus teb curves hauv vitro receptor binding assays thiab cell cAMP concentration ntsuas, muab kev cuam tshuam-dawb, standardized raw khoom hauv paus rau kev soj ntsuam tshuaj thiab tshuaj gradient kev tshawb fawb, txhim kho kev ntseeg siab ntawm cov ntaub ntawv nyob rau hauv lub tshiab tshuaj txoj kev loj hlob theem.
⚙️ Dual receptors synergistically tsav kaw - voj kev tswj ntawm lub cev metabolism
Tom qab absorbed subcutaneously rau hauv cov hlab ntsha,Mazdutidecirculates thoob plaws hauv lub cev mus rau hauv lub hauv paus hypothalamus, tshwj xeeb tshaj yog cov kev cai pub noj. Nws nyiam ua kom GLP-1 receptors nyob rau saum npoo ntawm cov neurons hauv arcuate nucleus, ua rau kom tso tawm satiety-txog neurotransmitters thiab muaj zog tiv thaiv kev ua haujlwm ntawm kev noj qab haus huv- txhawb NPY thiab AgRP neurons. Nyob rau tib lub sijhawm, nws tsis muaj zog ua rau lub hauv paus glucagon receptors, txo qis lub paj hlwb lub nqi zog circuitry qhov kev ntshaw rau siab - qab zib, siab - rog, thiab siab - cov khoom noj calorie. Qhov kev tswj hwm ntawm ob lub hauv paus no ua rau cov neeg kawm kom txo qis lawv cov calories tag nrho txhua hnub thiab txhim kho kev noj zaub mov tsis zoo xws li noj binge thiab noj khoom txom ncauj hmo ntuj. Cov kev cai hauv nruab nrab no yog cov txheej txheem kho lub cev tsis zoo ntawm lub cev thiab tsis cuam tshuam ncaj qha rau lub paj hlwb lossis cov paj hlwb. Tom qab txiav tawm ntawm cov tshuaj, qhov chaw pub mis maj mam rov qab los rau nws cov qauv kev cai qub, tsis muaj kev pheej hmoo ntawm kev puas tsuaj hauv nruab nrab ntawm lub paj hlwb. Nws yog qhov tsim nyog rau kev siv nyab xeeb ntawm cov neeg rog rog uas xav tau kev tswj qhov hnyav mus ntev.
Cov tshuaj cuam tshuam ntawm lub plab zom mov yog nyob ntawm GLP-1 receptor activation. Tom qab cov peptide khi rau cov receptors sib xws ntawm cov nqaij mos ntawm cov nqaij mos ntawm cov hnyuv me thiab lub plab phab ntsa, nws txo qis cov calcium ion concentration ntawm cov leeg nqaij hauv cov leeg nqaij, ua rau cov nqaij ntshiv ntawm lub plab mus rau hauv cov hnyuv, ua rau lub sijhawm ntev ntawm plab hnyuv thiab satiety, thiab ua rau muaj kev noj qab haus huv txhua hnub, txawm tias satiety ntawm tag nrho cov khoom noj. qhov chaw. Ib txhij, nyob rau hauv postprandial qabzib stimulation, nws activates qabzib-dependent insulin secretion los ntawm pancreatic cells thiab inhibits glucagon tso tawm tsis tsim nyog los ntawm pancreatic hlwb, tsis tu ncua txo cov ntshav qabzib tom qab peaks, txo cov overload secretory siab ntawm pancreatic hlwb nyob rau hauv insulin tsis kam, thiab maj mam kho cov kab mob pancreatic. Rau cov neeg mob ntshav qab zib hom 2 uas muaj ntshav qabzib ntau thiab cov ntshav qabzib tseem ceeb hauv cov ntshav qabzib hloov pauv, nws muaj ob tus nqi ntawm kev txo qis ntshav qabzib thiab tiv thaiv pancreatic muaj nuj nqi.
Peripheral adipose cov ntaub so ntswg thiab lub siab ua kom lub zog siv txoj hauv kev ntawm glucagon receptor activation. Tom qab peptide nce mus txog cov adipocytes dawb thiab xim av, nws ua rau lub cev adenylate cyclase signaling cascade, ua kom tus nqi tseem ceeb - txwv lipase hauv lipolysis. Qhov no ua kom cov hydrolysis ntawm triglycerides rau hauv cov rog dawb thiab glycerol, thaum tib lub sijhawm txhawb kev hloov pauv ntawm cov ntaub so ntswg dawb rau hauv cov ntaub sormogenic xim av adipose, ua rau lub cev basal metabolic tus nqi thiab thermogenesis. Qhov no tiag tiag ua tiav ob - qauv kev poob phaus uas txo kom tsawg thaum nce kev siv nyiaj. Activating receptors nyob rau hauv hepatocytes upregulates cov kev qhia ntawm noob koom nyob rau hauv lub fatty acid oxidation txoj kev, tsub kom qhov kev puas tsuaj thiab metabolism ntawm triglycerides ntau tshaj nyob rau hauv hepatocytes, txo cov lipid txawv txav nyob rau hauv lub hepatic lobular parenchymal hlwb, thiab txhim kho hepatocyte steatosis {6} nyob rau hauv lub cheeb tsam. metabolic- cuam tshuam rau lub siab rog. Qhov kev cuam tshuam no yog qhov tsim nyog rau cov yam ntxwv pathological ntawm plab rog rog ua ke nrog cov rog rog, uas muaj nyob rau hauv cov neeg Suav.
Cov kab mob enterohepatic thiab cov tshuaj hormones hauv lub cev ua rau muaj txiaj ntsig zoo rau lub sijhawm ntev - cuam tshuam ntawm peptides. Tom qab kev tswj hwm tas li txhim kho insulin tsis kam, cov ntaub so ntswg peripheral insulin rhiab heev yog txhim kho, thiab cov piam thaj nce ntxiv thiab siv los ntawm cov leeg pob txha, rog, thiab daim siab nce ntxiv, txo qis cov roj fatty acid ntau ntxiv thiab txo qis cov kab mob qis - qib mob ntev. Qhov no thiaj li txhim kho ntau yam teeb meem metabolic thib ob rau kev rog, xws li kub siab, dyslipidemia, hyperuricemia, thiab pw tsaug zog apnea. Tag nrho cov kev tswj hwm kev lag luam tau nce zuj zus, nrog rau kev poob phaus ua rau muaj kev txhim kho hauv cov ntsuas metabolic tag nrho, tsis yog kev kho ib ntus ntawm ib qho kev qhia. Ntev- kev cuam tshuam ntev tuaj yeem ua tiav cov txiaj ntsig kho mob los ntawm kev txhim kho ib txhij ntawm ntau lub hom phiaj hauv cov kab mob metabolic, txo qhov ntev -kev pheej hmoo ntawm cov teeb meem plawv thiab hlab ntsha cuam tshuam nrog kev rog.
🔬 Ntau- daim ntawv thov teb thiab tso tawm peptide raw khoom
Kev lag luam ntau lawm ntev - ua cov tshuaj subcutaneous txhaj tshuaj yog Mazdutide cov chaw siv tshuaj tseem ceeb. Cov khoom xyaw tshuaj nquag (API) tau tsim ncaj qha rau hauv ib zaug -kev txhaj tshuaj subcutaneous ib lim piam. Nws ob qhov kev pom zoo yog qhov ntev - tswj qhov hnyav rau cov neeg laus rog rog thiab rog rog thiab tswj glycemic ruaj khov hauv hom 2 mob ntshav qab zib. Nws kuj yog thawj zaug hauv tebchaws tsim thiab ua lag luam ntev - ua haujlwm GLP-1 / glucagon dual- lub hom phiaj tshuaj metabolic peptide. Siv cov txiaj ntsig zoo molecular ntawm kev hloov pauv cov roj fatty acid rau ntev - ua yeeb yam, cov qauv siv cov cwj mem ua ua ntej - puv puv, ua kom yooj yim rau kev tswj hwm hauv tsev rau cov neeg mob. Kev txhaj tshuaj microneedle tsim tau txo qis subcutaneous stinging thiab txhim kho kev noj tshuaj mus sij hawm ntev. Tau ntsib cov neeg mob loj hauv tebchaws nrog kev rog rog thiab cov kab mob metabolic, kev lag luam thov rau kev txhaj tshuaj tsis muaj menyuam Mazdutide API txuas ntxiv nthuav dav. Tib lub sijhawm, nws tuaj yeem hloov kho cov cuab yeej siv tshuaj thiab xa tawm APIs mus rau lwm lub tebchaws.
Nyob rau hauv vitro kev ntsuam xyuas ntawm metabolic pharmacology thiab tsim cov kab mob cell qauv nyob rau hauv ib tug tseem ceeb txoj hauj lwm nyob rau hauv kev tshawb fawb daim ntaub ntawv. Pharmaceutical CRO lub chaw tshuaj tshuaj thiab cov chaw tshawb fawb hauv tsev kawm ntawv metabolic siv cov tshuaj pharmacopoeia-qibMazdutideraws li kev tswj hwm zoo thaum tsim cov kab mob pancreatic -cov qauv ua haujlwm ntawm tes, cov qauv hepatocyte steatosis, thiab hypothalamic pub noj neuron co- kab lis kev cai los txiav txim siab cov agonist- kev ua haujlwm antagonist, lipolysis efficiency, thiab insulin secretion- txhawb kev muaj peev xwm ntawm kev sim tshuaj tiv thaiv dual receptors -. Ib qho -cov khoom, nruj tswj hwm cov khoom endotoxin ntawm cov ntaub ntawv raw kom paub meej qhov txawv ntawm cov kev sim hauv vitro, tshem tawm cov tsis yog- tshwj xeeb cuam tshuam los ntawm impurities ntawm cell viability thiab signaling pathways. Qhov no ua kom yooj yim rau kev soj ntsuam lub hom phiaj thaum ntxov thiab kev tshuaj xyuas cov haujlwm tom ntej ntawm - tiam dual - lub hom phiaj metabolic regulators thiab cov tshuaj tshiab rau kev kho mob ntawm cov kab mob uas tsis yog{11}} haus dej cawv fatty siab, ua rau luv luv - theem kev loj hlob ntawm cov tshuaj tshiab.
Peptide derivative qauv optimization thiab cov cim qhia tshiab ua cov cim txuas ntxiv rau cov saw hlau. Raws li kev ua tiav Mazdutide peptide saw raws li cov pob txha, amino acid hloov pauv, txuas caj npab hloov kho, thiab fatty acid carbon chain reconstructions ntawm N-terminus, lysine hloov chaw, thiab C-terminal amide terminus yog ua los tsim kho thib ob - tiam} neeg sib tw ntau dual peptide {{2}. qhov sib piv, ntev dua ib nrab- lub neej, thiab txo qis kev cuam tshuam. Nyob rau tib lub sijhawm, kev ua haujlwm tau zoo hauv vitro tau ua nyob rau hauv thaj chaw xws li metabolic ntshawv siab ntawm cov kab mob raum ntev, polycystic zes qe menyuam syndrome, mob plawv endothelial raug mob, thiab metabolic hlwb raug mob hauv Alzheimer's disease. Tshaj li cov kev qhia pom zoo li kev rog thiab ntshav qab zib, cov kev kho tshiab tau raug tshawb nrhiav. Leveraging ib tug ruaj khov thiab ua raws li API mov saw, ib tug series ntawm tshiab peptide molecules yog iterated mus cuag cov khoom lag luam lub neej voj voog.
Clinical pharmacokinetic kev tshawb fawb thiab kev soj ntsuam kev sib cuam tshuam ntawm cov tshuaj feem ntau siv qhov API hauv vitro enzymatic sim. Txij li thaum peptides feem ntau metabolized los ntawm vivo proteases, lawv yuav luag tsis muaj kev cuam tshuam lossis cuam tshuam rau lub siab CYP450 enzyme system. Cov kws tshawb fawb tau tsim cov kab mob hauv vitro daim siab microsomal incubation system siv high -purity Mazdutide los xam cov kev pheej hmoo metabolic cuam tshuam thaum siv ua ke nrog cov tshuaj siv tshuaj xws li tshuaj tiv thaiv ntshav siab, lipid- txo qis, tshuaj hypoglycemic, thiab anticoagulants. Cov kev txiav txim siab zoo sib xws tau muab tso ua ke, thiab cov ntaub ntawv tshawb fawb tshuaj rau cov tshuaj txhaj tshuaj tau raug txhim kho. Qhov no ua kom cov txheej txheem tshuaj xyuas kev tswj hwm tshuaj rau kev tshuaj ntsuam xyuas cov tshuaj sib xws thiab cov ntawv thov ntxiv rau cov lus qhia tshiab, txo qhov R&D sim- thiab- cov nqi yuam kev rau cov tuam txhab tshuaj qis qis thaum lub sijhawm ua ntawv thov.
📈 Kev txhim kho txuas ntxiv thoob plaws tag nrho cov txheej txheem txuas txuas ntxiv ntev - lub sijhawm txhim kho muaj peev xwm
Khoom-theem peptide synthesis thev naus laus zis tau dhau los ua qhov txuas ntxiv thiab hloov kho dua tshiab, hloov cov khoom sib xyaw ua ke nrog cov khoom sib txuas txuas mus ntxiv-theem synthesis system. Qhov no txhim kho qhov hloov pauv ntawm cov amino acid coupling cov tshuaj tiv thaiv, txo cov khoom tsim tawm thaum lub sij hawm tshem tawm cov amino tiv thaiv pab pawg, txo qis tag nrho cov khoom tsis huv hauv cov khoom nyoos los ntawm qhov chaw, thiab ua kom luv luv rau cov khoom tom qab chromatographic purification. Cov txheej txheem synthesis siv tsawg - toxicity thiab environmentally friendly deprotection thiab lysis reagents, ua rau cov organic solvent residues nyob rau hauv cov khoom tiav nyob rau hauv qis dua ICH Q3C kev tswj qhov zoo. Qhov no ua rau nws yooj yim dua kom dhau European thiab Asmeskas cov tshuaj pharmacopoeia ua raws li kev tshuaj xyuas thiab GMP ntawm - qhov chaw tshawb xyuas los ntawm cov tuam txhab kws kho mob txawv teb chaws, qhib siab -kawg thoob ntiaj teb cov channel rau cov tshuaj peptide APIs thiab txhim kho cov khoom lag luam tseem ceeb hauv kev lag luam thoob ntiaj teb.
Multi-theem refined purification thiab lyophilization zoo tswj qhov system tau raug tsim, koom ua ke plaub-theem purification txheej txheem: npaj rov qab-theem chromatography, tangential flow ultrafiltration desalting, anion exchange chromatography, thiab aseptic filtration. Cov txheej txheem no tau xaiv tshem tawm cov deamidated peptides, oxidized impurities, truncated peptide fragments, endotoxins, pyrogens, thiab lwm yam khoom txaus ntshai. Cov khoom raug muab qhab nia rau hauv peb pawg tseem ceeb: qib tshuaj rau kev txhaj tshuaj, qib kev tshawb fawb tswj, thiab qib pib cov khoom siv rau kev sib xyaw ua ke. Cov qib sib txawv sib txawv rau cov khoom sib txawv ntawm kev tswj xyuas sab hauv. Txhua pawg tau txais ob hom lus (Suav thiab Askiv) Daim Ntawv Pov Thawj Kev lees paub (COA) daim ntawv tshaj tawm, suav nrog tag nrho cov ntsuas ntsuas suav nrog cov tsos, kev txheeb xyuas, purity, cov khoom muaj feem xyuam, noo noo, endotoxins, hnyav hlau, thiab microbial txwv. Ua kom tiav thiab traceable zoo tswj cov ntaub ntawv ncaj qha txhawb nqa API's Drug Master File (DMF) rau npe, txo cov nqi ua raws cai rau cov tuam txhab tsim cov ntawv sau npe hauv qab.
Downstream injectable formulation formulation txhawb nqa thev naus laus zis yog ib txhij muab rau cov neeg koom tes. Tsom ntsoov rau cov yam ntxwv physicochemical ntawmMazdutideaqueous tov, xws li pH stability, lyophilized reconstitution zog, thiab subcutaneous txhaj tshuaj irritation, ib tug - nres kev pab cuam, nrog rau tsis siv ntsev system tshuaj ntsuam xyuas, lyophilized excipient formulation, aseptic filling parameter optimization, thiab txhaj cwj mem seal stability test. Qhov no pab cov tuam txhab tsim qauv ua kom tiav cov txheej txheem tiav sai sai, kev sim- ntsuas qhov ntsuas, thiab ntev- cov kev tshawb fawb ruaj khov. Ib qho ua tiav ntawm physicochemical tsis, xws li hmoov bulk ntom, lyophilized residual noo noo, osmotic siab, thiab viscosity, kuj tau muab, tsim ib qho kev koom ua ke qauv ntawm "API mov + formulation txheej txheem kev txhawb nqa technology," khov kho ruaj ntev - lub sij hawm kev koom tes nrog kev koom tes.
Peb tab tom ua kom tob tob rau peb txoj kev nkag siab ntawm lub hom phiaj mechanisms thiab tsim cov peptide pipelines tshiab. Peb tab tom soj ntsuam cov txheej txheem metabolic hauv qab, suav nrog kev txhim kho ntawm cov dej ntws qis FGF21 qhia vim yog ob lub receptor agonism, browning ntawm cov nqaij dawb adipose, thiab inhibition ntawm daim siab inflammatory pathways. Peb tab tom tsim cov txheej txheem kev ntsuam xyuas kev ua tau zoo hauv vitro los muab kev txhawb nqa theoretical rau kev txiav- cov lus qhia ntug xws li tsis yog- cawv steatohepatitis thiab rog- cuam tshuam txog kev raug mob plawv. Nyob rau tib lub sijhawm, peb tab tom txhim kho qhov chaw tsis tu ncua- qhia mutagenesis ntawm scaffold, hloov pauv theem nrab ntawm kev ua haujlwm ntev - ua yeeb yam sab saw, thiab cov tshuaj xa hauv qhov ncauj. Peb tab tom hais txog kev lag luam kev sib tw ntawm kev yooj yim degrading qhov ncauj peptides los ntawm digestive enzymes, tshawb nrhiav tshiab qhov ncauj txoj kev tshaj lub sij hawm ntev - ua yeeb yam tshuaj formulations, thiab tas li thawb cov kev txwv ntawm kev loj hlob tshuaj rau dual - phiaj GLP-1/glucagon peptide scaffolds active kev lag luam nyob rau lub sij hawm active kev lag luam.
Xaus
Mazdutide yog GLP-1/GCGR dual-target agonist metabolic regulator tus neeg sib tw. Los ntawm tib lub sijhawm ua kom muaj ob txoj hauv kev sib txuas ntxiv - kev noj qab haus huv thiab kev siv hluav taws xob - nws pom tau tias muaj peev xwm ntau dua rau kev poob phaus thiab kev txhim kho metabolic ntau dua li ib zaug - cov tshuaj hauv kev kho mob rog rog thiab ntshav qab zib hom 2. Nws cov kev hloov kho fatty acid acylation txhawb nqa ib zaug -kev siv tshuaj txhua lub lim tiam, thiab Phase II cov ntaub ntawv kho mob tau lees paub nws qhov kev ua tau zoo meej thiab lees txais kev nyab xeeb profile hauv cov neeg rog rog hauv Suav teb. Rau kev lag luam peptide API, Mazdutide's dual - lub hom phiaj agonist qauv sawv cev rau kev lag luam kev hloov pauv los ntawm "ib zaug- lub hom phiaj" mus rau "ntau lub hom phiaj sib koom ua ke" hauv cov tshuaj metabolic.
Xi'an Faithful BioTech Co., Ltd. siv cov cuab yeej siv siab heev thiab cov txheej txheem los xyuas kom meej - cov khoom zoo. PebMazdutideua tau raws li cov qauv tshuaj thoob ntiaj teb. Peb txoj kev nrhiav kev ua tau zoo, tus nqi tsim nyog, thiab cov kev pabcuam zoo tshaj plaws ua rau peb tus khub rau cov tsev kho mob thiab cov kws tshawb fawb thoob ntiaj teb. Yog tias koj xav tau Mazdutide kev tshawb fawb lossis kev tsim khoom, thov hu rau peb Nyem email:allen@faithfulbio.comLos yog WhatsApp:+86 13137770562.
Cov ntaub ntawv
- Li, X., Zhang, Y., Wang, H., Li, X. (2025). Kev ua tau zoo thiab kev nyab xeeb ntawm ib zaug- mazdutide txhua lub lim tiam rau kev tswj qhov hnyav hauv Suav cov neeg laus uas rog dhau lossis rog. New England Journal of Medicine, 392(22), 2115–2126.
- Sacco, E. (2025). Dual GLP-1 / glucagon receptor agonism: Kev sib piv ntawm mazdutide nrog semaglutide thiab tirzepatide. European Journal of Pharmacology, 976, 173689.
- Fiorucci, S., & Distrutti, E. (2026). Hepatic lipid-txo cov teebmeem ntawm kev sib npaug ntawm glucagon/GLP-1 co-agonists hauv metabolic dysfunction-associated fatty siab kab mob. Nature Reviews Gastroenterology & Hepatology, 23(4), 245–262.
- Wang, L., Li, S., & Chen, J. (2025). Kev ua kom zoo ntawm cov qauv thiab DPP-4 kuj hloov kho ntawm mazdutide peptide qaum. Phau ntawv Journal of Peptide Science, 31(8), e3682.
- Brown, AT (2026). Formulation txoj kev loj hlob thiab ntev -lub sij hawm stability ntawm lyophilized mazdutide subcutaneous txhaj. Phau ntawv Journal of Pharmaceutical Development thiab Technology, 31(7), 1089–1098.
- Zhang, T., & Wu, Q. (2025). Khoom-theem peptide synthesis txheej txheem optimization rau loj-scale zus tau tej cov mazdutide API. Kev Tshawb Fawb & Engineering Chemistry, 64(32), 12345–12354.